Lipids and lipid nanoparticle formulations for delivery of nucleic acids

Inventors

Ansell, Steven M. • Du, Xinyao

Assignees

Acuitas Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11648324-B2

Patent

Publication Date

2023-05-16

Expiration Date


Abstract

Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Core Innovation

The invention is directed to novel cationic (amino) lipid compounds defined by a structure and multiple structural variants. The disclosure includes pharmaceutically acceptable forms of the compounds, including salts, and also covers tautomers and stereoisomers. The disclosure provides structural representations for multiple amphiphilic lipid-like compounds and compounds C00076–C00092.

The structures show repeating fatty-hydrocarbon chains attached to polar functional groups including hydroxyls, amines/nitrogen, and ester/carbonyl moieties. The disclosed compounds are intended to form lipid nanoparticles with other lipid components, including neutral lipids, cholesterol or steroids, charged lipids, and polymer/PEG-conjugated lipids. The disclosure describes lipid nanoparticle concepts including nuclease/serum stability and formulation concepts for delivering nucleic acid therapeutics.

The nucleic acid therapeutics described include messenger RNA (mRNA), antisense oligonucleotides, miRNA inhibitors, siRNA, and plasmids. The disclosure further describes compound combinations involving a compound of Structure (I) and pegylated lipid options, and the disclosed LNP compositions comprise the cationic lipid of Structure (I) together with neutral lipid, cholesterol, and a PEG-lipid having the pegylated lipid structure (II), together with a therapeutic agent, including nucleic acids and messenger RNA (mRNA).

Claims Coverage

The provided independent claims cover defined compound structures, including stereoisomers and pharmaceutically acceptable salts, and extend to lipid nanoparticles comprising those compounds, lipid nanoparticles further including messenger RNA, and pharmaceutical compositions including the compound and/or the lipid nanoparticle with pharmaceutically acceptable carriers, diluents, or excipients. There are 4 main inventive feature areas: the defined compound structure, the lipid nanoparticle including the compound, optional messenger RNA in the lipid nanoparticle, and pharmaceutical compositions with acceptable formulation components.

Defined cationic amino lipid compound structure

A compound having the following structure, or a stereoisomer or pharmaceutically acceptable salt thereof.

Lipid nanoparticle comprising the defined compound

A lipid nanoparticle that includes the compound having the following structure, or a stereoisomer or pharmaceutically acceptable salt thereof.

Lipid nanoparticle including messenger RNA

A lipid nanoparticle that further includes a messenger RNA.

Pharmaceutical composition including the defined compound with acceptable formulation components

A pharmaceutical composition including the compound having the following structure, together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Pharmaceutical composition including a messenger-RNA lipid nanoparticle with acceptable formulation components

A pharmaceutical composition including a lipid nanoparticle together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim coverage centers on defined compound structures, including stereoisomers and pharmaceutically acceptable salts, and extends to lipid nanoparticles comprising those compounds, including messenger RNA as an additional component, and pharmaceutical compositions that incorporate either the compound and/or the lipid nanoparticle with pharmaceutically acceptable carriers, diluents, or excipients.

Stated Advantages

Serum protection.

Improved in vivo activity.

Improved tolerability.

Increased therapeutic index.

Cellular delivery in vitro and in vivo.

Documented Applications

Delivering nucleic acid therapeutics using lipid nanoparticles, including messenger RNA (mRNA), antisense oligonucleotides, miRNA inhibitors, siRNA, and plasmids.

Nuclease/serum stability concepts associated with lipid nanoparticles for nucleic acid delivery.

Cellular delivery in vitro and in vivo using the described lipid nanoparticle formulations.

Luciferase mRNA (FLuc mRNA) delivery using LNP compositions in mouse models, with reported liver luciferase activity and correlated pKa data [procedural detail omitted for safety].

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.